Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Paolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar-Sela, Felix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno, Antoni Ribas

Research output: Contribution to journalLetterpeer-review

Fingerprint

Dive into the research topics of 'Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds